Last reviewed 2026-05-19 · How we verify

ABP-745 Dose B

Atom Therapeutics Co., Ltd · Phase 2 active Small molecule ✓ Verified May 2026 Quality 0/100

ABP-745 Dose B is a Small molecule drug developed by Atom Therapeutics Co., Ltd. It is currently in Phase 2 development.

ABP-745 Dose B is a small molecule intervention being studied in a clinical trial for conditions including acute gouty arthritis and atherosclerosis cardiovascular disease. The study, NCT07145229, is a randomized, double-blind, multicenter trial comparing ABP-745 Dose B to colchicine in participants with an acute gout flare.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ABP-745 Dose B
Sponsor	Atom Therapeutics Co., Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ABP-745 Dose B CI brief — competitive landscape report
ABP-745 Dose B updates RSS · CI watch RSS
Atom Therapeutics Co., Ltd portfolio CI

Frequently asked questions about ABP-745 Dose B

What is ABP-745 Dose B?

ABP-745 Dose B is a Small molecule drug developed by Atom Therapeutics Co., Ltd.

Who makes ABP-745 Dose B?

ABP-745 Dose B is developed by Atom Therapeutics Co., Ltd (see full Atom Therapeutics Co., Ltd pipeline at /company/atom-therapeutics-co-ltd).

What development phase is ABP-745 Dose B in?

ABP-745 Dose B is in Phase 2.

Manufacturer: Atom Therapeutics Co., Ltd — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing